<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588937</url>
  </required_header>
  <id_info>
    <org_study_id>361HBV15017</org_study_id>
    <nct_id>NCT02588937</nct_id>
  </id_info>
  <brief_title>Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antiviral activity and safety of EntecaBell ODT.&#xD;
      in chronic hepatitis B Patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of subjects who showed HBV DNA undetected (less than 300copies/mL)</measure>
    <time_frame>48 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBV DNA undetected (less than 300copies/mL)</measure>
    <time_frame>24 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Difference between the baseline and at the 24, 48 week of HBV DNA level(log10)</measure>
    <time_frame>24, 48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBeAg serum loss</measure>
    <time_frame>24, 48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBeAg seroconversion</measure>
    <time_frame>24, 48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBsAg serum loss</measure>
    <time_frame>48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed HBsAg seroconversion</measure>
    <time_frame>48 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of subjects who showed Virologic breakthrough</measure>
    <time_frame>12, 24, 48 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>EntecaBell ODT.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Baraclude Tab.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EntecaBell ODT. 0.5mg</intervention_name>
    <arm_group_label>EntecaBell ODT.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baraclude Tab. 0.5mg</intervention_name>
    <arm_group_label>Baraclude Tab.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Over the age of 20 years old&#xD;
&#xD;
          2. Patients with Chronic Hepatitis B diagnosed&#xD;
&#xD;
          3. Patients who show positive HBsAg&#xD;
&#xD;
          4. Patients who show positive HBeAg or negative HBeAg&#xD;
&#xD;
          5. Patients who showed HBV DNA undetected(less than 300 copies/mL)&#xD;
&#xD;
          6. Patients who have administered Baraclude Tab. 0.5mg for 1~4 years&#xD;
&#xD;
          7. Patients who showed ALT less than 5 times of the upper limit in the normal range&#xD;
&#xD;
          8. Patient who decided to participate and signed on an informed consent form willingly&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have hepatitis C (HCV), hepatitis D (HDV), or human immunodeficiency&#xD;
             virus (HIV)&#xD;
&#xD;
          2. Patients with a uncompensated liver disease who have at least one of the following&#xD;
             values or signs&#xD;
&#xD;
               -  Total bilirubin &gt; 2.5mg/dl&#xD;
&#xD;
               -  Prothrombin time delayed more than three seconds of upper limit in the normal&#xD;
                  range&#xD;
&#xD;
               -  Serum Albumin &lt; 3 g/dL&#xD;
&#xD;
               -  A medical history of ascites, jaundice, hemorrhage by varix, hepatic&#xD;
                  encephalopathy, or other signs of liver function loss&#xD;
&#xD;
          3. Patients who are estimated to have hepatocellular carcinoma (HCC) through imaging&#xD;
             examination or showed alpha-fetoprotein(AFP) more than 100 ng/mL&#xD;
&#xD;
          4. Patients who showed Creatinine Clearance &lt; 50 mL/min by calculating Cockcroft-Gault&#xD;
             equation&#xD;
&#xD;
          5. Patients who were not administered any anti-viral agents except Baraclude&#xD;
             Tab.(Entecavir)&#xD;
&#xD;
          6. Administration of other Investigational Product within 30 days&#xD;
&#xD;
          7. History of malignant tumor within 5 years (including leukemia and lymphoma)&#xD;
&#xD;
          8. Patients who have a severe disease, such as heart failure, renal failure, and&#xD;
             pancreatitis, decided by an investigator to have an effect on this clinical trial&#xD;
&#xD;
          9. Patients who have other hepatic diseases except hepatitis B&#xD;
&#xD;
         10. Administration immunosuppressants or corticosteroids over 2 weeks within 24 weeks&#xD;
&#xD;
         11. Patients who have to administer immunosuppressants or Nephrotoxic drugs, Hepatotoxic&#xD;
             drugs for period of Clinical Trial&#xD;
&#xD;
         12. Pregnant, breast-feeding and childbearing age who don't use adequate contraception&#xD;
&#xD;
         13. Patients who are possible to decline daily function due to a mental disease or&#xD;
             patients who are not able to understand the purpose and methods of this clinical trial&#xD;
&#xD;
         14. Patients who received an organ transplant or are going to received an organ transplant&#xD;
&#xD;
         15. Severe hypersensitivity to Entecavir&#xD;
&#xD;
         16. Another clinical condition in investigator's judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Konkuk University Chungju Hospital</name>
      <address>
        <city>Chungju</city>
        <state>Chungcheongbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Cheonan</city>
        <state>ChungCheongnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Chungcheongnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeong sangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <state>Jeju-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>December 12, 2016</last_update_submitted>
  <last_update_submitted_qc>December 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Entecavir, EntecaBell ODT., Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

